Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) insider Lara Longpre sold 1,004 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $25.65, for a total transaction of $25,752.60. Following the sale, the insider now directly owns 105,839 shares in the company, valued at approximately $2,714,770.35. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Mirum Pharmaceuticals Stock Performance
Shares of NASDAQ MIRM opened at $26.25 on Friday. The company’s fifty day moving average price is $26.92 and its 200 day moving average price is $24.26. Mirum Pharmaceuticals, Inc. has a 1 year low of $17.32 and a 1 year high of $30.55. The company has a market capitalization of $998.29 million, a PE ratio of -7.19 and a beta of 1.27.
Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) last announced its quarterly earnings results on Thursday, May 4th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.16. Mirum Pharmaceuticals had a negative net margin of 134.90% and a negative return on equity of 91.76%. The firm had revenue of $31.60 million for the quarter, compared to the consensus estimate of $30.58 million. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -2.97 EPS for the current year.
Analysts Set New Price Targets
Institutional Trading of Mirum Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in MIRM. Endurance Wealth Management Inc. raised its position in Mirum Pharmaceuticals by 179.1% during the fourth quarter. Endurance Wealth Management Inc. now owns 1,954 shares of the company’s stock worth $38,000 after acquiring an additional 1,254 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Mirum Pharmaceuticals during the first quarter worth $49,000. Belpointe Asset Management LLC acquired a new position in Mirum Pharmaceuticals during the first quarter worth $67,000. Legal & General Group Plc raised its position in Mirum Pharmaceuticals by 2,193.7% during the second quarter. Legal & General Group Plc now owns 6,583 shares of the company’s stock worth $128,000 after acquiring an additional 6,296 shares during the period. Finally, Knights of Columbus Asset Advisors LLC acquired a new position in Mirum Pharmaceuticals during the first quarter worth $174,000.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
Recommended Stories
- Five stocks we like better than Mirum Pharmaceuticals
- Order From U.S. Army Fuels Surge In Enovix Stock
- The Bottom Is In For Mullen Automotive
- Could Meta Be Risking Another Sell Off With Its New “Threads”?
- 2 Must-Have Specialized ETFs for the Long-Term Investor
- Inspire Medical Up 15% After Breakout, Analysts Say It’s A Buy
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
